A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination with Anti-cancer Agents in Adult Participants with Tumours Harbouring a KRASG12D Mutation

Trial Identifier: D7080C00001
Sponsor: AstraZeneca
Start Date: October 2024
Primary Completion Date: January 2028
Study Completion Date: January 2028
Condition: Cancer - Other; Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
BE Edegem, BE, 2650
BE Leuven, BE, 3000
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, Ontario Toronto, Ontario, CA, M5G 1X5
CA, QC Montréal, QC, CA, H3A 1A1
CN Beijing, CN, 100142
CN Chengdu, CN, 610041
CN Zhengzhou, CN, 450008
ES Barcelona, ES, 08035
ES L'Hospitalet de Llobregat, ES, 08908
ES Madrid, ES, 28007
ES Madrid, ES, 28027
ES Valencia, ES, 46026
GB Cambridge, GB, CB2 0QQ
GB Manchester, GB, M20 4BX
GB Newcastle-Upon-Tyne, GB, NE7 7DN
HK Hong Kong, HK, 999077
IT Milano, IT, 20132
IT Napoli, IT, 80131
IT Verona, IT, 37134
JP Kashiwa, JP, 227-8577
JP Tokyo, JP, 104-0045
KR Seoul, KR, 06351
KR Seoul, KR, 5505
KR Seoul, KR, 120-752
KR Seoul, KR, 03080
NL Amsterdam, NL, 1066CX
PL Gdańsk, PL, 80-214
PL Łódź, PL, 93-513
TH Bangkok, TH, 10400
TH Bangkok, TH, 10700
TR Ankara, TR, 06800
TR Istanbul, TR, 34718
US, CA Duarte, CA, US, 91010
US, CA Stanford, CA, US, 94305-5847
US, NY New York, NY, US, 10016
US, TN Nashville, TN, US, 37203
US, TX San Antonio, TX, US, 78229
US, VA Fairfax, VA, US, 22031